Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Autor: Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T., van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., Levin, Mark-David

Publikováno v: In Blood 28 September 2023 142(13):1131-1142

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Autor: Kater, Arnon P ^*, Levin, Mark-David, Dubois, Julie, Kersting, Sabina, Enggaard, Lisbeth, Veldhuis, Gerrit J, Mous, Rogier, Mellink, Clemens H M, van der Kevie-Kersemaekers, Anne-Marie F, Dobber, Johan A, Poulsen, Christian B, Frederiksen, Henrik, Janssens, Ann, Schjødt, Ida, Dompeling, Ellen C, Ranti, Juha, Brieghel, Christian, Mattsson, Mattias, Bellido, Mar, Tran, Hoa T T, Nasserinejad, Kazem, Niemann, Carsten U ^**

Publikováno v: In The Lancet Oncology June 2022 23(6):818-828

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes

Autor: Santos, Joana, Cerveira, Nuno, Bizarro, Susana, Ribeiro, Franclim R., Correia, Cecília, Torres, Lurdes, Lisboa, Susana, Vieira, Joana, Mariz, José M., Norton, Lucília, Snijder, Simone, Mellink, Clemens H., Buijs, Arjan, Shih, Lee-Yung, Strehl, Sabine, Micci, Francesca, Heim, Sverre, Teixeira, Manuel R.

Publikováno v: In Leukemia Research 2010 34(5):615-621

Both SEPT2 and MLL are down-regulated in MLL-SEPT2 therapy-related myeloid neoplasia

Autor: Mariz José M, Snijder Simone, Vieira Joana, Torres Lurdes, Correia Cecília, Lisboa Susana, Ribeiro Franclim R, Costa Vera, Bizarro Susana, Santos Joana, Cerveira Nuno, Norton Lucília, Mellink Clemens H, Buijs Arjan, Teixeira Manuel R

Publikováno v: BMC Cancer, Vol 9, Iss 1, p 147 (2009)

Abstract Background A relevant role of septins in leukemogenesis has been uncovered by their involvement as fusion partners in MLL-related leukemia. Recently, we have established the MLL-SEPT2 gene fusion as the molecular abnormality subjacent to the

Externí odkaz: https://doaj.org/article/c22d4d68225f4829a16df50784cdd999